Matthew J. Sale

Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Annette S. Little, Kathryn Balmanno, Matthew J. Sale et al. · Science Signaling · 2011 · 204 citations

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

Claire L. Cope, Rebecca Gilley, Kathryn Balmanno et al. · Journal of Cell Science · 2013 · 78 citations · Full text

Engineering, Kinase Inhibitors, Chronic Mtor Complex +21

Can EDA combat the rise of electronic counterfeiting?

Farinaz Koushanfar, Saverio Fazzari, Carl McCants et al. · 2012 · 77 citations

Hardware Trojan, Electronic Counterfeiting, Engineering +20

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Matthew J. Sale, Emma Minihane, Noel R. Monks et al. · Nature Communications · 2019 · 72 citations · Full text

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

C Winkler, Joshua Armenia, Gemma N. Jones et al. · British Journal of Cancer · 2020 · 68 citations · Full text